122 related articles for article (PubMed ID: 37845827)
1. Increased hippocampal blood flow in people at clinical high risk for psychosis and effects of cannabidiol.
Davies C; Bossong MG; Martins D; Wilson R; Appiah-Kusi E; Blest-Hopley G; Zelaya F; Allen P; Brammer M; Perez J; McGuire P; Bhattacharyya S
Psychol Med; 2024 Apr; 54(5):993-1003. PubMed ID: 37845827
[TBL] [Abstract][Full Text] [Related]
2. Effect of Cannabidiol on Medial Temporal, Midbrain, and Striatal Dysfunction in People at Clinical High Risk of Psychosis: A Randomized Clinical Trial.
Bhattacharyya S; Wilson R; Appiah-Kusi E; O'Neill A; Brammer M; Perez J; Murray R; Allen P; Bossong MG; McGuire P
JAMA Psychiatry; 2018 Nov; 75(11):1107-1117. PubMed ID: 30167644
[TBL] [Abstract][Full Text] [Related]
3. Interactions between hippocampal activity and striatal dopamine in people at clinical high risk for psychosis: relationship to adverse outcomes.
Modinos G; Richter A; Egerton A; Bonoldi I; Azis M; Antoniades M; Bossong M; Crossley N; Perez J; Stone JM; Veronese M; Zelaya F; Grace AA; Howes OD; Allen P; McGuire P
Neuropsychopharmacology; 2021 Jul; 46(8):1468-1474. PubMed ID: 33941857
[TBL] [Abstract][Full Text] [Related]
4. A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis.
Davies C; Wilson R; Appiah-Kusi E; Blest-Hopley G; Brammer M; Perez J; Murray RM; Allen P; Bossong MG; McGuire P; Bhattacharyya S
Transl Psychiatry; 2020 Sep; 10(1):311. PubMed ID: 32921794
[TBL] [Abstract][Full Text] [Related]
5. Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis.
Appiah-Kusi E; Petros N; Wilson R; Colizzi M; Bossong MG; Valmaggia L; Mondelli V; McGuire P; Bhattacharyya S
Psychopharmacology (Berl); 2020 Apr; 237(4):1121-1130. PubMed ID: 31915861
[TBL] [Abstract][Full Text] [Related]
6. Increased Striatal and Reduced Prefrontal Cerebral Blood Flow in Clinical High Risk for Psychosis.
Kindler J; Schultze-Lutter F; Hauf M; Dierks T; Federspiel A; Walther S; Schimmelmann BG; Hubl D
Schizophr Bull; 2018 Jan; 44(1):182-192. PubMed ID: 28575528
[TBL] [Abstract][Full Text] [Related]
7. Oxytocin modulates hippocampal perfusion in people at clinical high risk for psychosis.
Davies C; Paloyelis Y; Rutigliano G; Cappucciati M; De Micheli A; Ramella-Cravaro V; Provenzani U; Antoniades M; Modinos G; Oliver D; Stahl D; Murguia S; Zelaya F; Allen P; Shergill S; Morrison P; Williams S; Taylor D; McGuire P; Fusar-Poli P
Neuropsychopharmacology; 2019 Jun; 44(7):1300-1309. PubMed ID: 30626906
[TBL] [Abstract][Full Text] [Related]
8. Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis.
O'Neill A; Wilson R; Blest-Hopley G; Annibale L; Colizzi M; Brammer M; Giampietro V; Bhattacharyya S
Psychol Med; 2021 Mar; 51(4):596-606. PubMed ID: 31994476
[TBL] [Abstract][Full Text] [Related]
9. Effects of cannabidiol (CBD) on regional cerebral blood flow.
Crippa JA; Zuardi AW; Garrido GE; Wichert-Ana L; Guarnieri R; Ferrari L; Azevedo-Marques PM; Hallak JE; McGuire PK; Filho Busatto G
Neuropsychopharmacology; 2004 Feb; 29(2):417-26. PubMed ID: 14583744
[TBL] [Abstract][Full Text] [Related]
10. Don't Fear the Reefer-Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy.
Perry MS
Epilepsy Curr; 2019; 19(2):93-95. PubMed ID: 30955420
[TBL] [Abstract][Full Text] [Related]
11. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial.
Schoedel KA; Szeto I; Setnik B; Sellers EM; Levy-Cooperman N; Mills C; Etges T; Sommerville K
Epilepsy Behav; 2018 Nov; 88():162-171. PubMed ID: 30286443
[TBL] [Abstract][Full Text] [Related]
12. The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study.
Bloomfield MAP; Green SF; Hindocha C; Yamamori Y; Yim JLL; Jones APM; Walker HR; Tokarczuk P; Statton B; Howes OD; Curran HV; Freeman TP
J Psychopharmacol; 2020 Sep; 34(9):981-989. PubMed ID: 32762272
[TBL] [Abstract][Full Text] [Related]
13. Resting Hyperperfusion of the Hippocampus, Midbrain, and Basal Ganglia in People at High Risk for Psychosis.
Allen P; Chaddock CA; Egerton A; Howes OD; Bonoldi I; Zelaya F; Bhattacharyya S; Murray R; McGuire P
Am J Psychiatry; 2016 Apr; 173(4):392-9. PubMed ID: 26684922
[TBL] [Abstract][Full Text] [Related]
14. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment.
Englund A; Morrison PD; Nottage J; Hague D; Kane F; Bonaccorso S; Stone JM; Reichenberg A; Brenneisen R; Holt D; Feilding A; Walker L; Murray RM; Kapur S
J Psychopharmacol; 2013 Jan; 27(1):19-27. PubMed ID: 23042808
[TBL] [Abstract][Full Text] [Related]
15. Parsing neurobiological heterogeneity of the clinical high-risk state for psychosis: A pseudo-continuous arterial spin labelling study.
Oliver D; Davies C; Zelaya F; Selvaggi P; De Micheli A; Catalan A; Baldwin H; Arribas M; Modinos G; Crossley NA; Allen P; Egerton A; Jauhar S; Howes OD; McGuire P; Fusar-Poli P
Front Psychiatry; 2023; 14():1092213. PubMed ID: 36970257
[TBL] [Abstract][Full Text] [Related]
16. The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.
Boggs DL; Surti T; Gupta A; Gupta S; Niciu M; Pittman B; Schnakenberg Martin AM; Thurnauer H; Davies A; D'Souza DC; Ranganathan M
Psychopharmacology (Berl); 2018 Jul; 235(7):1923-1932. PubMed ID: 29619533
[TBL] [Abstract][Full Text] [Related]
17. Increased Resting Hippocampal and Basal Ganglia Perfusion in People at Ultra High Risk for Psychosis: Replication in a Second Cohort.
Allen P; Azis M; Modinos G; Bossong MG; Bonoldi I; Samson C; Quinn B; Kempton MJ; Howes OD; Stone JM; Calem M; Perez J; Bhattacharayya S; Broome MR; Grace AA; Zelaya F; McGuire P
Schizophr Bull; 2018 Oct; 44(6):1323-1331. PubMed ID: 29294102
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis.
Gunasekera B; Wilson R; O'Neill A; Blest-Hopley G; O'Daly O; Bhattacharyya S
Psychol Med; 2023 Jul; 53(10):4732-4741. PubMed ID: 35775365
[TBL] [Abstract][Full Text] [Related]
19. Neural Circuitry of Novelty Salience Processing in Psychosis Risk: Association With Clinical Outcome.
Modinos G; Allen P; Zugman A; Dima D; Azis M; Samson C; Bonoldi I; Quinn B; Gifford GWG; Smart SE; Antoniades M; Bossong MG; Broome MR; Perez J; Howes OD; Stone JM; Grace AA; McGuire P
Schizophr Bull; 2020 Apr; 46(3):670-679. PubMed ID: 32227226
[TBL] [Abstract][Full Text] [Related]
20. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers.
Perkins D; Butler J; Ong K; Nguyen TH; Cox S; Francis B; Mcintosh M; Lilley B
Eur J Drug Metab Pharmacokinet; 2020 Oct; 45(5):575-586. PubMed ID: 32409982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
